Read our latest white paper, which takes published ISPOR trends and analyses the insights to identify and explore three disruptors and three enablers that can facilitate your company’s ability to successfully deliver value and access in the future.
Three disruptors in the future of market access:
- Science & technology
- Assessment systems & evidence requirements
- Funding & payment systems
Three enablers in the future of market access:
- Anticipating the future
- Removing the barriers
- Establishing winning differentiation
Armed with these insights, you can inform and influence R&D and commercial decision-making inside your organisation. You will also understand and be able to communicate the consequences and benefits of collaborating with other stakeholders outside your organisation, to shape the future healthcare and market access environment.
Find our solution here.
Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.